V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 11.9 DKK -1.65% Market Closed
Market Cap: 92.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ViroGates A/S
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Other Long-Term Assets
kr2.4B
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
3%
Ambu A/S
CSE:AMBU B
Other Long-Term Assets
kr160m
CAGR 3-Years
56%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Other Long-Term Assets
kr548m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
7%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
92.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.15 DKK
Overvaluation 73%
Intrinsic Value
Price
V

See Also

Back to Top